Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push Read more →

Merck and Sarah Cannon team up to boost oncology trial efficiency Read more →

Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss Read more →